Literature DB >> 8151391

Technetium-99m-tetrofosmin to assess myocardial blood flow: experimental validation in an intact canine model of ischemia.

A J Sinusas1, Q Shi, M T Saltzberg, P Vitols, D Jain, F J Wackers, B L Zaret.   

Abstract

UNLABELLED: Technetium-99m-tetrofosmin is a 99mTc-labeled perfusion tracer demonstrating promise for myocardial perfusion imaging. To determine if 99mTc-tetrofosmin tracks myocardial flow over a pathophysiologic range, the initial myocardial uptake and clearance of 99mTc-tetrofosmin relative to microsphere flow were evaluated in a canine model of ischemia during pharmacological vasodilatation.
METHODS: Six open-chest dogs were subjected to complete left anterior descending coronary artery occlusion. Dogs were injected with 99mTc-tetrofosmin and radiolabeled microspheres during pharmacological stress. Coincident with radiotracer injection, dynamic planar imaging and arterial sampling were performed to assess 99mTc-tetrofosmin clearance from blood, myocardium, lung and liver. Fifteen minutes after injection, hearts were excised for well counting of myocardial 99mTc-tetrofosmin activity and flow.
RESULTS: Myocardial 99mTc-tetrofosmin activity correlated linearly with microsphere flow (r = 0.84). Relative 99mTc-tetrofosmin activity underestimated flow at higher flow ranges (> 2.0 ml/min/g) and overestimated flow in low flow ranges (< 0.2 ml/min/g). Technetium-99m-tetrofosmin cleared rapidly from the blood and was retained in the myocardium. Resting target-to-background activity ratios (heart:lung = 3.57 +/- 1.01; heart:liver = 0.58 +/- 0.04) were acceptable 10 min after injection.
CONCLUSION: Our experimental data support both the validity of 99mTc-tetrofosmin as a myocardial perfusion tracer and the use of early poststress 99mTc-tetrofosmin imaging for the assessment of myocardial perfusion in man.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8151391

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  35 in total

1.  The challenge of quantifying defect size and severity: reality versus algorithm.

Authors:  R L Eisner; R E Patterson
Journal:  J Nucl Cardiol       Date:  1999 May-Jun       Impact factor: 5.952

Review 2.  An overview of radiotracers in nuclear cardiology.

Authors:  W Acampa; C Di Benedetto; A Cuocolo
Journal:  J Nucl Cardiol       Date:  2000 Nov-Dec       Impact factor: 5.952

3.  Diagnostic and prognostic applications for vasodilator stress myocardial perfusion imaging and the importance of radiopharmaceutical selection.

Authors:  R C Hendel
Journal:  J Nucl Cardiol       Date:  2001 Jul-Aug       Impact factor: 5.952

Review 4.  Comparison of Tl-201 with Tc-99m-labeled myocardial perfusion agents: technical, physiologic, and clinical issues.

Authors:  P Kailasnath; A J Sinusas
Journal:  J Nucl Cardiol       Date:  2001 Jul-Aug       Impact factor: 5.952

Review 5.  Myocardial perfusion imaging agents: SPECT and PET.

Authors:  George A Beller; Steven R Bergmann
Journal:  J Nucl Cardiol       Date:  2004 Jan-Feb       Impact factor: 5.952

6.  Assessment of myocardial perfusion with Tc-99m: image is everything.

Authors:  Seth T Dahlberg
Journal:  J Nucl Cardiol       Date:  2009-04-30       Impact factor: 5.952

7.  Myocardial uptake of 7'-(Z)-[(123)I]iodorotenone during vasodilator stress in dogs with critical coronary stenoses.

Authors:  Alexis Broisat; Mirta Ruiz; Norman C Goodman; Stephen M Hanrahan; Bryan W Reutter; Kathleen M Brennan; Mustafa Janabi; Saul Schaefer; Denny D Watson; George A Beller; Henry F VanBrocklin; David K Glover
Journal:  Circ Cardiovasc Imaging       Date:  2011-09-14       Impact factor: 7.792

Review 8.  Experimental evaluation of radiotracers: role of intact biological models.

Authors:  A J Sinusas
Journal:  J Nucl Cardiol       Date:  1998 Mar-Apr       Impact factor: 5.952

9.  Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial.

Authors:  Rami Doukky; Maria Octavia Rangel; Rizcallah Dick; Marwan Wassouf; Ammar Alqaid; Bosko Margeta
Journal:  Int J Cardiovasc Imaging       Date:  2012-12-11       Impact factor: 2.357

10.  Enhanced detection of reversible myocardial hypoperfusion by technetium 99m-tetrofosmin imaging and first-pass radionuclide angiography after nitroglycerin administration.

Authors:  A Peix; A López; F Ponce; J Morales; A R de la Vega; C S Chesa; A M Maltas; D García-Barreto
Journal:  J Nucl Cardiol       Date:  1998 Sep-Oct       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.